drugset
drugset / Trial / NCT04269356

Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants

NCT04269356 ↗

Phase 1 Completed 8 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the way the body absorbs, distributes, breaks down and eliminates radioactive BMS-986856 in healthy males.

Timeline

Start
2020-02-18
Primary completion
2021-03-30
Completion
2021-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Afimetoran Small molecule — —
Background Milk of Magnesia Unknown — —

Indications

No indication recorded.